AI Article Synopsis
- The SOLOIST-WHF trial demonstrated the effectiveness of sotagliflozin in patients with diabetes experiencing worsening heart failure, but its cost-effectiveness had not been studied before.
- The study created a Markov model to analyze the long-term cost and health outcomes of sotagliflozin, utilizing data from the trial and other national sources.
- Results showed that while sotagliflozin increased quality-adjusted life-years (QALYs) and lifetime costs compared to placebo, its incremental cost-effectiveness ratio suggests that it is a cost-effective treatment under common willingness-to-pay thresholds.
Article Abstract
Background: The efficacy of sotagliflozin in patients with diabetes and recent worsening of heart failure was shown in the SOLOIST-WHF trial. However, the cost-effectiveness of sotagliflozin in these patients has not been previously investigated.
Objectives: The authors sought to determine the cost-effectiveness of sotagliflozin in patients with diabetes and recent worsening of heart failure.
Methods: Based on SOLOIST-WHF trial data (N = 1,222), the authors constructed a Markov model to estimate the lifetime impact of sotagliflozin from a U.S. health care sector perspective. Cost data were sourced from the National Inpatient Sample. Life expectancy was modeled from census data and modified by the mortality rate in SOLOIST-WHF. Fatal and nonfatal event rates were carried forward from the trial data. Utility was assessed from the published reports.
Results: Lifetime quality-adjusted life-years (QALYs) were 4.43 and 4.04 in the sotagliflozin and placebo groups, respectively, and lifetime costs were $220,113 and $188,198 in the sotagliflozin and placebo groups, respectively. The point estimate incremental cost-effectiveness ratio was $81,823 per QALY gained. The probability of being cost-effective was 3.6%, 67.5%, and 89.4% at willingness-to-pay thresholds of $50,000, $100,000, and $150,000, respectively, per QALY gained.
Conclusions: In patients with diabetes and recent worsening of heart failure, sotagliflozin is cost-effective in the U.S. using commonly accepted willingness-to-pay thresholds. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchf.2024.04.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mathematical modeling for prediction of physicochemical characteristics of cardiovascular drugs via modified reverse degree topological indices.
Eur Phys J E Soft Matter
August 2024
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11461, Saudi Arabia.
Article Synopsis
- Global health issues related to heart diseases are complicated by factors like lifestyle choices, genetics, and new complications from COVID-19, expanding the range of cardiovascular conditions needing attention.
- Effective management of these heart conditions requires timely interventions, including lifestyle changes and medications such as beta-blockers and antiplatelets.
- The study focuses on using modified reverse degree topological indices in drug development, analyzing 30 cardiovascular drug compounds to create quantitative structure-property relationship (QSPR) models that outperform traditional degree-based models.
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF.
JACC Heart Fail
September 2024
Christiana Care Health System, Newark, Delaware, USA.
Article Synopsis
- The SOLOIST-WHF trial demonstrated the effectiveness of sotagliflozin in patients with diabetes experiencing worsening heart failure, but its cost-effectiveness had not been studied before.
- The study created a Markov model to analyze the long-term cost and health outcomes of sotagliflozin, utilizing data from the trial and other national sources.
- Results showed that while sotagliflozin increased quality-adjusted life-years (QALYs) and lifetime costs compared to placebo, its incremental cost-effectiveness ratio suggests that it is a cost-effective treatment under common willingness-to-pay thresholds.
Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure.
J Comp Eff Res
June 2024
FTI Consulting, Center for Healthcare Economics & Policy, Washington, DC 20004, USA.
Article Synopsis
- A cost-effectiveness model was developed to evaluate sotagliflozin for heart failure patients with diabetes, looking at hospital readmissions, emergency visits, and mortality over a 30-year period.
- Sotagliflozin resulted in significant reductions in rehospitalizations (34.5%), emergency visits (40.0%), and mortality (18.0%) compared to standard care, providing a net gain of 0.425 quality-adjusted life years (QALYs).
- The analysis showed that while the use of sotagliflozin increased costs by $19,374 over 30 years, its incremental cost-effectiveness ratio (ICER) was $45,596 per QALY, indicating it is a
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
Am J Cardiovasc Drugs
January 2024
Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
Article Synopsis
- Rivaroxaban 2.5 mg twice daily combined with aspirin was more effective than aspirin alone for preventing serious cardiovascular events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD).
- A cost-analysis over a 23-month follow-up showed that while the total costs for the combination treatment were higher ($7,426), it provided an extra 1.17 quality-adjusted life years (QALYs), resulting in a favorable incremental cost-effectiveness ratio (ICER) of $23,295/QALY.
- The study concludes that using rivaroxaban with aspirin is a cost-effective strategy in the U.S., making it a valuable option for managing cardiovascular health in these patients.
A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes.
Ann Pharmacother
May 2024
Taneja College of Pharmacy and Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Article Synopsis
- Bexagliflozin is shown to lower hemoglobin A1c levels by about 0.5%, along with similar decreases in blood pressure and weight compared to other SGLT2 inhibitors, though there are currently no published cardiovascular outcome trials.
- The drug’s side effects are comparable to other SGLT2 inhibitors, including risks of genital infections, urinary tract infections, and increased urination, with a specific warning about lower extremity amputation.
- While bexagliflozin has no available cost-effectiveness data and lacks extensive trial data, it may offer a competitive price; however, other SGLT2 inhibitors like empagliflozin or dapaglif
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!